Complete genomic organization and promoter analysis of the round-spotted pufferfish JAK1, JAK2, JAK3, and TYK2 genes

被引:45
|
作者
Leu, JH
Yan, SJ
Lee, TF
Chou, CM
Chen, ST
Hwang, PP
Chou, CK
Huang, CJ
机构
[1] Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan
[2] Acad Sinica, Inst Zool, Taipei 115, Taiwan
[3] Vet Gen Hosp, Dept Med Res, Taipei 11217, Taiwan
关键词
D O I
10.1089/10445490050085924
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have previously reported the isolation of the JAK1 gene from the round-spotted pufferfish, In the present study, nle cloned and characterized genomic sequences encoding pufferfish JAK2, JAK3, and TYK2, which are other members of JAK family, To our knowledge, this is the first report to demonstrate the existence of four JAK genes in fish. All pufferfish JAK genes except JAK1 are composed of 24 exons; JAK1 has an additional exon, A comparison of the exon-intron organization of these genes revealed that the splice sites of JAK genes are nearly identical. In addition, all pufferfish JAK genes have one intron in the 5' untranslated region. Taken together, these data suggest that the pufferfish JAK genes may have evolved from a common ancestor. By 5' rapid amplification of cDNA ends and sequence analysis, me deduced the promoter regions for all JAK genes and found they do not contain typical TATA or CCAAT boxes but rather numerous other potential binding sites for transcription factors. Interestingly, the TYK2 gene is linked to CDC37 in a head-to-tail manner with a small intergenic region of 292 bp, Within this region, there are two potential binding sites for transcriptional factors such as c-Myb and NF-IL6, The putative promoter regions of all JAK genes were tested either in a carp CF cell line or in zebrafish embryos using CAT or lacZ as reporter genes. Both assays confirmed the transcriptional activities of these promoters in vitro and in vivo.
引用
收藏
页码:431 / 446
页数:16
相关论文
共 50 条
  • [41] Immunohistochemical analysis of the JAK family members in inflammatory skin diseases reveals increased expression of JAK1 and JAK3
    de Medeiros, A. K. Alves
    De Schepper, S.
    Lambert, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S12 - S12
  • [42] Preclinical characterization of JAK1/JAK2 inhibitors for treatment of type 1 diabetes
    Scott, N. A.
    Trivedi, P. M.
    Graham, K. L.
    Fynch, S.
    Jenkins, M. R.
    Kay, T. W.
    Thomas, H. E.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 361 - 361
  • [43] Therapeutic potential of a synthetic dual JAK1/TYK2 inhibitor in inflammatory bowel disease
    Cui, Xue
    Teng, Yaxin
    Hu, Yiguo
    Li, Qingqing
    Pei, Heying
    Yang, Zhuang
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 126
  • [44] Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation
    RodriguezLinares, B
    Watson, SP
    BIOCHEMICAL JOURNAL, 1996, 316 : 93 - 98
  • [45] Inhibitors of JAK2 and JAK3: an update on the patent literature 2010-2012
    Dymock, Brian W.
    See, Cheng Shang
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (04) : 449 - 501
  • [46] Mutations of JAK2, JAK3 and GATA1 in acute megakaryoblastic leukemia of Down syndrome
    Hama, Asahito
    Yagasaki, Hiroshi
    Takahashi, Yoshiyuki
    Matsumoto, Kimikazu
    Kiyoi, Hitoshi
    Kojima, Seiji
    BLOOD, 2008, 111 (04) : 2493 - 2494
  • [47] THE JAK1/JAK2 INHIBITOR, RUXOLITINIB SUBSTANTIALLY AFFECTS NK CELL BIOLOGY
    Schoenberg, K.
    Janna, R.
    Cornez, I.
    Brossart, P.
    Wolf, D.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S74 - S75
  • [48] The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib
    Choy, E. H. S.
    Miceli-Richard, C.
    Gonzalez-Gay, M. A.
    Sinigaglia, L.
    Schlichting, D. E.
    Meszaros, G.
    de la Torre, I.
    Schulze-Koops, H.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (04) : 694 - 704
  • [49] A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses
    Kohlhuber, F
    Rogers, NC
    Watling, D
    Feng, J
    Guschin, D
    Briscoe, J
    Witthuhn, BA
    Kotenko, SV
    Pestka, S
    Stark, GR
    Ihle, JN
    Kerr, IM
    MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (02) : 695 - 706
  • [50] JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis
    Wu, Junchao
    Li, Lisha
    Zhu, Quangang
    Zhang, Tingrui
    Miao, Fengze
    Cui, Zhen
    Dong, Guoqiang
    Tai, Zongguang
    Chen, Zhongjian
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 171